OneSource Specialty Pharma Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
2,289
- Stock Symbol
-
544292
- Investments
-
2
- Share Price
-
$17.16
- (As of Friday Closing)
OneSource Specialty Pharma General Information
Description
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segment is CDMO (Contract Development and ManufacturingOrganization (CDMO) : Development and manufacture of pharmaceutical products and associated services).
Contact Information
Website
www.onesourcecdmo.comCorporate Office
- Star 1, Opposite IIM Bangalore
- Bilekahalli, Bannerghatta Road
- Bengaluru, Karnataka 560076
- India
Corporate Office
- Star 1, Opposite IIM Bangalore
- Bilekahalli, Bannerghatta Road
- Bengaluru, Karnataka 560076
- India
OneSource Specialty Pharma Stock Performance
As of 13-Nov-2026, OneSource Specialty Pharma’s stock price is $17.16. Its current market cap is $1.97B with 115M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.16 | $17.26 | $11.71 - $21.09 | $1.97B | 115M | 47.8K |
OneSource Specialty Pharma Financials Summary
As of 30-Sep-2026, OneSource Specialty Pharma has a trailing 12-month revenue of $182M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,972,837 | 1,898,180 | 2,398,367 | |
| Revenue | 181,605 | 160,879 | 170,873 | 20,767 |
| EBITDA | 42,519 | 32,401 | 40,818 | (24,874) |
| Net Income | (175) | (8,352) | (2,125) | (47,250) |
| Total Assets | 893,907 | 870,142 | 882,664 | 156,920 |
| Total Debt | 182,699 | 159,396 | 110,176 | 68,491 |
OneSource Specialty Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OneSource Specialty Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
OneSource Specialty Pharma Comparisons
Industry
Financing
Details
OneSource Specialty Pharma Competitors (5)
One of OneSource Specialty Pharma’s 5 competitors is BDR Pharmaceuticals Internationals, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BDR Pharmaceuticals Internationals | Private Equity-Backed | Mumbai, India | ||||
| Kemwell Biopharma | Corporation | Bangalore, India | ||||
| Farbe Firma Pvt. | Corporation | Ankleshwar, India | ||||
| Axxelent Pharma Science Pvt | Corporation | Chennai, India | ||||
| Sovereign Pharmaceuticals | Corporate Backed or Acquired | Fort Worth, TX |
OneSource Specialty Pharma Patents
OneSource Specialty Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180037604-A1 | Process for the purification of recombinant proteins | Inactive | 04-Aug-2016 | ||
| US-20140221606-A1 | Aspart proinsulin compositions and methods of producing aspart insulin analogs | Inactive | 23-Feb-2011 | ||
| US-20160024168-A1 | Aspart proinsulin compositions and methods of producing aspart insulin analogs | Inactive | 23-Feb-2011 | ||
| US-20120214963-A1 | Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom | Inactive | 23-Feb-2011 | ||
| US-20120214965-A1 | Glargine proinsulin and methods of producing glargine insulin analogs therefrom | Inactive | 23-Feb-2011 | C07K14/62 |
OneSource Specialty Pharma Signals
OneSource Specialty Pharma Investments & Acquisitions (2)
OneSource Specialty Pharma’s most recent deal was a Merger/Acquisition with Brooks Steriscience. The deal was made on 12-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Brooks Steriscience | 12-Nov-2025 | Merger/Acquisition | Drug Discovery | ||
| Bioprocess Scale-up Lab (Merck/Stelis Biopharma) | 12-May-2017 | Joint Venture | Other Commercial Services |
OneSource Specialty Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
OneSource Specialty Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Stelis Biopharma (Manufacturing Unit In Bengaluru, India) | Bommasandra, India |
OneSource Specialty Pharma FAQs
-
When was OneSource Specialty Pharma founded?
OneSource Specialty Pharma was founded in 2007.
-
Where is OneSource Specialty Pharma headquartered?
OneSource Specialty Pharma is headquartered in Bengaluru, India.
-
What is the size of OneSource Specialty Pharma?
OneSource Specialty Pharma has 2,289 total employees.
-
What industry is OneSource Specialty Pharma in?
OneSource Specialty Pharma’s primary industry is Drug Discovery.
-
Is OneSource Specialty Pharma a private or public company?
OneSource Specialty Pharma is a Public company.
-
What is OneSource Specialty Pharma’s stock symbol?
The ticker symbol for OneSource Specialty Pharma is 544292.
-
What is the current stock price of OneSource Specialty Pharma?
As of 13-Nov-2026 the stock price of OneSource Specialty Pharma is $17.16.
-
What is the current market cap of OneSource Specialty Pharma?
The current market capitalization of OneSource Specialty Pharma is $1.97B.
-
What is OneSource Specialty Pharma’s current revenue?
The trailing twelve month revenue for OneSource Specialty Pharma is $182M.
-
Who are OneSource Specialty Pharma’s competitors?
BDR Pharmaceuticals Internationals, Kemwell Biopharma, Farbe Firma Pvt., Axxelent Pharma Science Pvt, and Sovereign Pharmaceuticals are competitors of OneSource Specialty Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process